These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30050494)

  • 1. Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease.
    Dolatshahi M; Pourmirbabaei S; Kamalian A; Ashraf-Ganjouei A; Yaseri M; Aarabi MH
    Front Neurol; 2018; 9():560. PubMed ID: 30050494
    [No Abstract]   [Full Text] [Related]  

  • 2. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
    Nabizadeh F; Pirahesh K; Valizadeh P
    J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
    Nabizadeh F; Pirahesh K; Ramezannezhad E
    Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in tremor-dominant Parkinson's disease.
    Nabizadeh F; Sodeifian F; Kargar A
    Acta Neurol Belg; 2023 Aug; 123(4):1429-1437. PubMed ID: 37000407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
    Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
    Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson's disease.
    Tao M; Dou K; Xie Y; Hou B; Xie A
    Front Neurosci; 2022; 16():1049118. PubMed ID: 36507360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
    Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
    BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarkers profile in scans without evidence of dopaminergic deficits (SWEDD).
    Nabizadeh F; KamaliZonouzi S; Noori M
    IBRO Neurosci Rep; 2023 Dec; 15():320-326. PubMed ID: 37953806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease.
    Parnetti L; Farotti L; Eusebi P; Chiasserini D; De Carlo C; Giannandrea D; Salvadori N; Lisetti V; Tambasco N; Rossi A; Majbour NK; El-Agnaf O; Calabresi P
    Front Aging Neurosci; 2014; 6():53. PubMed ID: 24744728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease.
    Kang JH
    J Mov Disord; 2016 May; 9(2):89-96. PubMed ID: 27240810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
    Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF Aβ
    Ba M; Yu G; Kong M; Liang H; Yu L
    Transl Neurodegener; 2018; 7():22. PubMed ID: 30338062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association of CSF sTREM2 With Cognitive Decline and Its Dynamic Change in Parkinson's Disease: Analysis of the PPMI Cohort.
    Qin Q; Wan H; Wang D; Li J; Qu Y; Zhao J; Li J; Xue Z
    Front Aging Neurosci; 2022; 14():892493. PubMed ID: 35783125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Majbour NK; Abdi IY; Dakna M; Wicke T; Lang E; Ali Moussa HY; Thomas MA; Trenkwalder C; Safieh-Garabedian B; Tokuda T; Mollenhauer B; El-Agnaf O
    Mov Disord; 2021 Sep; 36(9):2048-2056. PubMed ID: 33978256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olfactory impairment predicts cognitive decline in early Parkinson's disease.
    Fullard ME; Tran B; Xie SX; Toledo JB; Scordia C; Linder C; Purri R; Weintraub D; Duda JE; Chahine LM; Morley JF
    Parkinsonism Relat Disord; 2016 Apr; 25():45-51. PubMed ID: 26923521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.
    Compta Y; Valente T; Saura J; Segura B; Iranzo Á; Serradell M; Junqué C; Tolosa E; Valldeoriola F; Muñoz E; Santamaria J; Cámara A; Fernández M; Fortea J; Buongiorno M; Molinuevo JL; Bargalló N; Martí MJ
    J Neurol; 2015 Feb; 262(2):294-306. PubMed ID: 25380583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
    Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
    Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal trajectory of biofluid markers in Parkinson's disease.
    Baek MS; Lee MJ; Kim HK; Lyoo CH
    Sci Rep; 2021 Jul; 11(1):14820. PubMed ID: 34285331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.